Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.

Front Cardiovasc Med · 2022 · PMC9681904 · PMID 36440034

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In our study, we found that cardiac diastolic function showed a trend of improvement after the treatment with sacubitril/valsartan, demonstrated by the improvement of E/A ratio, TRVmax, septal e’ wave velocity, lateral e’ wave velocity, E/e’, and LAVI.

also in 53,322 other papers

a notable trendno p-value reported

New York Heart Association (NYHA) functional class showed a notable trend of improvement after 3–12 months of follow-up.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.